Literature DB >> 3789202

Kinetics of protein binding determine rates of uptake of drugs by brain.

P J Robinson, S I Rapoport.   

Abstract

A mathematical model describing the kinetics of binding and release of substances by plasma proteins is presented. The effects of protein binding on the uptake of substances such as drugs from the capillary network of the brain are discussed. The model assumes equilibration between bound and free forms of drug in arterial blood and incorporates the on-off rate constants for the drug-protein complex and rate constants for passage of free drug across the blood-brain barrier and for drug metabolism in the brain. Regional cerebral blood flow and the related capillary transit time are important parameters in the model. Analytical expressions for bound and free drug concentrations and for the net extraction of drug are derived where practicable, and numerical solutions also are presented. Effects of changes in the total drug and protein concentrations in the plasma are discussed with special reference to the uptake of bilirubin by the brain.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3789202     DOI: 10.1152/ajpregu.1986.251.6.R1212

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  13 in total

Review 1.  Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting: implications of the barriers between blood and brain.

Authors:  Elizabeth C M de Lange; Meindert Danhof
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons.

Authors:  M Vreugdenhil; C Bruehl; R A Voskuyl; J X Kang; A Leaf; W J Wadman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

Review 3.  Drug interactions at the renal level. Implications for drug development.

Authors:  P L Bonate; K Reith; S Weir
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

4.  In vivo labeling of brain phospholipids by long-chain fatty acids: relation to turnover and function.

Authors:  S I Rapoport
Journal:  Lipids       Date:  1996-03       Impact factor: 1.880

5.  Brain and plasma pharmacokinetics and anticancer activities of cyclophosphamide and phosphoramide mustard in the rat.

Authors:  S Genka; J Deutsch; P L Stahle; U H Shetty; V John; C Robinson; S I Rapoport; N H Greig
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 6.  In vivo fatty acid incorporation into brain phospholipids in relation to signal transduction and membrane remodeling.

Authors:  S I Rapoport
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

Review 7.  Toward the prediction of CNS drug-effect profiles in physiological and pathological conditions using microdialysis and mechanism-based pharmacokinetic-pharmacodynamic modeling.

Authors:  Elizabeth C M de Lange; Paulien G M Ravenstijn; Dorien Groenendaal; Tamara J van Steeg
Journal:  AAPS J       Date:  2005-10-07       Impact factor: 4.009

8.  Measurement of drug-protein dissociation rates by high-performance affinity chromatography and peak profiling.

Authors:  John E Schiel; Corey M Ohnmacht; David S Hage
Journal:  Anal Chem       Date:  2009-06-01       Impact factor: 6.986

9.  Physicochemical and pharmacokinetic parameters of seven lipophilic chlorambucil esters designed for brain penetration.

Authors:  N H Greig; S Genka; E M Daly; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

10.  Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography.

Authors:  John C Umhau; Weiyin Zhou; Richard E Carson; Stanley I Rapoport; Alla Polozova; James Demar; Nahed Hussein; Abesh K Bhattacharjee; Kaizong Ma; Giuseppe Esposito; Sharon Majchrzak; Peter Herscovitch; William C Eckelman; Karen A Kurdziel; Norman Salem
Journal:  J Lipid Res       Date:  2008-12-26       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.